Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/20070280
Conclusion of this study
EPs-7630 is effective in acute bronchitis outside the strict indication for antibiotics in 6-18 years old patients, with a dose of 60 mg or 90 mg daily offering the best benefit/risk ratio. EPs-7630 significantly reduces the severity of symptoms, leads to a more favourable course of the disease and a faster recovery from acute bronchitis compared with the placebo, and is well tolerated.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study